EGFR and non-small cell lung carcinoma: The efficacy of osimertinib has been validated in a phase III study (AURA3) that compared osimertinib with platinum-based doublet chemotherapy in advanced NSCLC patients that were positive for the T790M mutation of EGFR and whose tumors had progressed during previous EGFR-TKI therapy [13].